# A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

> **NCT06537310** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 34 (actual)

## Conditions studied

- Cancer-Neoplasms

## Interventions

- **DRUG:** RO7567132 and Atezolizumab
- **DRUG:** RO7567132 and Atezolizumab

## Key facts

- **NCT ID:** NCT06537310
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-16
- **Primary completion:** 2027-05-12
- **Final completion:** 2027-08-10
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06537310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06537310, "A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06537310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*